RP-3500

Phase 2Small molecule

RRepare Therapeutics

RP-3500 is one of 76 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Breast CancerRecruiting

Solid Tumor CancerActive, not recruiting

Solid TumorPhase 1

Recruiting

Breast CancerPhase 2

Recruiting

Solid Tumor CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zolymbus

AbbVie

Preclinical

1 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

RP-3500

RRepare Therapeutics

Phase 2

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Solid Tumor Cancer

NCT05566574

Q2 2028

Phase 1Recruiting

Solid Tumor

NCT04855656

Phase 2Recruiting

Breast Cancer

NCT05601440

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Completed·RRepare Therapeutics·Phase 1/2·NCT04497116·276 enrolled

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors

Terminated·RRepare Therapeutics·Phase 1/2·NCT04972110·156 enrolled

Solid Tumor Cancer1 trial

A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT05566574·49 enrolled

Chronic Lymphocytic Leukemia1 trial

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia

Terminated·UUniversity of Utah·Phase 1/2·NCT05405309·5 enrolled

Breast Cancer1 trial

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting·CCanadian Cancer Trials Group·Phase 2·NCT05601440·484 enrolled

Advanced Cancer1 trial

RP-6306 in Patients With Advanced Cancer

Completed·CCanadian Cancer Trials Group·Phase 2·NCT05605509·28 enrolled

1 more indication

Solid Tumor1 trial

Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Recruiting·DDebiopharm International SA·Phase 1·NCT04855656·464 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for RP-3500. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RP-3500 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RP-3500. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Repare Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRepare Therapeutics

RP-3500

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2028

Trials by Indication[1]

Advanced Solid Tumors2 trials

Solid Tumor Cancer1 trial

Chronic Lymphocytic Leukemia1 trial

Breast Cancer1 trial

Advanced Cancer1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News